Patricia Kay Zilliox

US Patent:

20040127472, Jul 1, 2004

Filed:

Jun 26, 2003

Appl. No.:

10/606501

Inventors:

Janice Jerdan - Arlington TX, US
Patricia Zilliox - Arlington TX, US
Stella Robertson - Fort Worth TX, US

International Classification:

A61K031/56

US Classification:

514/169000

Abstract:

Purpose: To evaluate clinical safety and efficacy of the angiostatic agent anecortave acetate for treatment of subfoveal choroidal neovascularization secondary to AMD. Methods: 128 patients were randomized to placebo treatment or one of three anecortave acetate doses. Study medication was administered as a posterior juxtascleral injection onto the posterior scleral surface. Best-corrected logMAR vision was obtained at Baseline and follow-up visits. Fluorescein angiograms were evaluated for eligibility prior to enrollment and post-treatment. Results: Six months after a single treatment, visual acuity (mean change from Baseline logMAR values) was significantly better (p=0.0032) after anecortave acetate 15 mg than placebo. More patients treated with anecortave acetate 15 mg than is placebo maintained vision (88% vs. 70%, p=0.0799), especially those with predominantly classic lesions (92% vs. 65%, p=0.0209). Anecortave acetate 15 mg inhibited lesion growth significantly better than placebo (p=0.0005). Trends favoring the other doses over placebo were observed for vision preservation and lesion inhibition, but statistical significance was not achieved. The Independent Safety Committee overseeing this study identified no clinically relevant treatment-related changes. Conclusion: Anecortave acetate 15 mg is safe and effective for preserving or improving vision and for inhibiting lesion growth in patients with subfoveal AMD.

US Patent:

20060166956, Jul 27, 2006

Filed:

Jun 26, 2003

Appl. No.:

10/521707

Inventors:

Janice Jerdan - Arlington TX, US
Patricia Zilliox - Arlington TX, US
Stella Robertson - Forth Worth TX, US

International Classification:

A61K 31/57

US Classification:

514178000

Abstract:

The present invention is directed to the use of anercortave acetate or the alcohol thereof for the protection of visual acuity in patients with age related macular degeneration.